Qiagen stock: EQT offer and Q3 update define pivotal week

QIAGEN's week was dominated by EQT's proposed takeover and the company's preliminary third-quarter update. On October 21, EQT agreed to acquire the molecular testing company in a cash transaction offering 46.50 euros per share, according to Reuters.

The transaction is expected to close in mid-2027, subject to regulatory clearances and other conditions. The tender offer has not yet started, so investors are still facing an announced transaction rather than a completed change of ownership.

Results Add a Second Catalyst

QIAGEN also reported preliminary third-quarter sales of 548 million USD at reported and constant exchange rates. Adjusted diluted earnings per share was 0.65 USD, according to the company's investor-relations release.

QIAGEN suspended its full-year 2026 outlook while the transaction is pending and will not hold a conference call for the preliminary results. The company plans to publish its complete third-quarter results on Wednesday, November 4, at approximately 22:05 Frankfurt time.

Qiagen stock traded at 45.05 euros on Lang & Schwarz at 10:41 CET on Saturday, October 31, 2026.

For investors, the offer price provides a reference point while regulatory review, shareholder conditions and the formal tender process remain ahead. The announced timetable leaves execution risk and the gap between the market quote and the cash consideration as key issues for the next phase.

European equities trade against a broader market backdrop tracked through the AEX market overview.

More news and analyses on Qiagen stock are available in the company topic section. Investors can also follow the real-time quote of Qiagen stock.